CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma CatalYm announced that the first patient has been dosed in the GDFATHER-HCC-01 trial The trial evaluates the company’s lead anti-GDF-15…
AIRNA Announces First Patient Dosed in Phase 1 Trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, announced the…
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases…
Abcuro Presents Results from Phase 2/3 MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis at GCOM 2026 Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026…
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Pfizer Inc. and Valneva SE announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524) of its…
PhaseWell Research Acquires Chase Medical Research to Expand Clinical Trial Capabilities in Connecticut PhaseWell Research a multisite clinical research company, today announced the strategic acquisition of Chase Medical Research (“CMR”). Under the leadership of founder, key opinion leader, and lead…
Meiji Seika Pharma Co., Ltd. has announced the initiation of a Phase I clinical trial for ME3241, an innovative anti-PD-1 agonist monoclonal antibody developed through a research collaboration with the Foundation for Biomedical Research and Innovation at Kobe (FBRI). The…
Genentech Reports Positive Phase II Results for Petrelintide, an Amylin Analog for Overweight and Obesity Genentech, a member of the Roche Group today announced positive topline results from the Phase II ZUPREME-1 trial evaluating the investigational drug petrelintide versus placebo…
Imagion Biosystems Advances Precision Cancer Imaging with FDA IND Filing for MagSense® Phase 2 Trial Imagion Biosystems, a molecular imaging company focused on transforming cancer detection and diagnosis, has announced a significant regulatory milestone with the submission of an Investigational…
Natera Unveils First Translational Insights From Phase III PALLAS Trial, Demonstrating Strong Prognostic Power of Signatera MRD Testing in HR+/HER2- Breast Cancer A global leader in cell-free DNA–based testing and precision oncology, has released the first translational research findings from…
Long-Term Data Demonstrate Safety and Preliminary Efficacy of Investigational One-Time Gene Therapy in Patients with Non-Ischemic Heart Failure AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced the publication…
Merck Publishes Long-Term Phase 3 DeFi Trial Results Demonstrating Sustained Efficacy and Safety of OGSIVEO® (nirogacestat) for Desmoid Tumors in Journal of Clinical Oncology Merck, a leading science and technology company, announced the publication of long-term efficacy and safety findings…